Abstract
Background: Modulated electro-hyperthermia (mEHT) is a variation of the conventional hyperthermia which selectively targets the malignant cell membranes in order to heat the malignant tissue and sensitize the tissue to oncology treatments. Although widely applied, the formulation of guidelines for the use thereof is still in progress for many tumors.Aim: In this paper we review the literature on the effects of mEHT in cancer patients on local disease control and survival.Methodology: Our review on data presents the collected experience with capacitive hyperthermia treatments with the EHY-2000+ device (OncoTherm Ltd., Germany). A literature search was conducted in Pubmed and articles were grouped and discussed according to: trial type, animal studies, in vitro studies, and reviews. Search results from Conference s; Trial Registries; Thesis and Dissertations and the Oncothermia Journal were included in the discussions.Results: Modulated electro-hyperthermia is a safe form of hyperthermia which has shown to effectively sensitizes deep tumors, regardless of the thickness of the adipose layers. The technology has demonstrated equal benefits compared to other forms of hyperthermia for a variety of tumors. Given the effective heating ability to moderate temperatures, the improved tumor perfusion, and ability to increase drug absorption, mEHT is a safe and effective heating technology which can be easily applied to sensitize tumors which have demonstrated benefits with the addition of hyperthermia. Modulated electro-hyperthermia also appears to improve local control and survival rates and appears to induce an abscopal (systemic) response to ionizing radiation.Conclusion: Based on clinical studies, the method mEHT is a feasible hyperthermia technology for oncological applications. Concomitant utilization of mEHT is supported by the preclinical and clinical data.
Highlights
Moderate hyperthermia in oncology refers to the process of heating a tumor to within a range of 39–42.5◦C in order to sensitize the tumor to oncology treatments [1]
A literature search was conducted in Pubmed using the string: “Cancer OR neoplasm OR tumor OR malignancies AND Oncothermia OR Oncotherm OR modulated electrohyperthermia OR modulated electrohyperthermia” with truncated words included in the search
One of major challenges in hyperthermia is the safe treatment of tumors of the central nervous system and brain
Summary
Moderate hyperthermia in oncology refers to the process of heating a tumor to within a range of 39–42.5◦C in order to sensitize the tumor to oncology treatments [1]. The survival benefit is not always as significant as the local disease control with the addition of hyperthermia [10,11,12,13,14] and a reduction in metastatic (systemic) disease is needed in order to improve survival rates. This could be achieved with the induction of a systemic response to the treatment. Modulated electro-hyperthermia (mEHT) is a variation of the conventional hyperthermia which selectively targets the malignant cell membranes in order to heat the malignant tissue and sensitize the tissue to oncology treatments. The formulation of guidelines for the use thereof is still in progress for many tumors
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
